Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis

NEXT STORY
Global Infection Control Market (2018 to 2027) – Increasing Use of E-Beam Sterilization Presents Opportunities
PREV STORY
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Healthcare IT Leader, Provation, Donates Clinical Documentation Software to Fiji’s Colonial War Memorial Hospital

author_avatar
NASDAQ Market News

Advanced Bactericidal and Viricidal Coatings Market Size is Projected to Grow at 11.7% CAGR by 2028 – Research Insights on Key Trends, Macro-economic Indicators, Strategic Initiatives and Future Prospect: Adroit Market Research

author_avatar
NASDAQ Market News

Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lung Cancer Compound CK-101

NEW YORK, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (OTCQX:CKPT), a ...

author_avatar
NASDAQ Market News